Determining the structure and mechanism of the human multidrug resistance P-glycoprotein using cysteine-scanning mutagenesis and thiol-modification techniques.

The multidrug resistance P-glycoprotein is an ATP-dependent drug pump that extrudes a broad range of hydrophobic compounds out of cells. Its physiological role is likely to protect us from exogenous and endogenous toxins. The protein is important because it contributes to the phenomenon of multidrug resistance during AIDS and cancer chemotherapy. We have used cysteine-scanning mutagenesis and thiol-modification techniques to map the topology of the protein, show that both nucleotide-binding domains are essential for activity, examine packing of the transmembrane segments, map the drug-binding site, and show that there is cross-talk between the ATP-binding sites and the transmembrane segments.

[1]  A. Schinkel,et al.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.

[2]  C. Higgins,et al.  Structure of the Multidrug Resistance P-glycoprotein to 2.5 nm Resolution Determined by Electron Microscopy and Image Analysis* , 1997, The Journal of Biological Chemistry.

[3]  F. Baas,et al.  The tissue dependent expression of hamster P‐glycoprotein genes , 1988, FEBS letters.

[4]  D. Clarke,et al.  Functional consequences of proline mutations in the predicted transmembrane domain of P-glycoprotein. , 1993, The Journal of biological chemistry.

[5]  T. Nishi,et al.  Transmembrane Topography of the 100-kDa a Subunit (Vph1p) of the Yeast Vacuolar Proton-translocating ATPase* , 1999, The Journal of Biological Chemistry.

[6]  J. H. Beijnen,et al.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.

[7]  P. Gros,et al.  Membrane topology of P-glycoprotein as determined by epitope insertion: transmembrane organization of the N-terminal domain of mdr3. , 1995, Biochemistry.

[8]  D. Clarke,et al.  Functional consequences of glycine mutations in the predicted cytoplasmic loops of P-glycoprotein. , 1994, The Journal of biological chemistry.

[9]  F. Sharom.  The P-Glycoprotein Efflux Pump: How Does it Transport Drugs? , 1997, The Journal of Membrane Biology.

[10]  B. Sankaran,et al.  Both P-glycoprotein Nucleotide-binding Sites Are Catalytically Active (*) , 1995, The Journal of Biological Chemistry.

[11]  D. Roden,et al.  The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.

[12]  S. Vik,et al.  Membrane Topology of Subunit a of the F1F0 ATP Synthase as Determined by Labeling of Unique Cysteine Residues* , 1998, The Journal of Biological Chemistry.

[13]  D. Koshland,et al.  Disulfide cross-linking studies of the transmembrane regions of the aspartate sensory receptor of Escherichia coli. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D. Clarke,et al.  Prolonged association of temperature-sensitive mutants of human P-glycoprotein with calnexin during biogenesis. , 1994, The Journal of biological chemistry.

[15]  D. Clarke,et al.  Covalent Modification of Human P-glycoprotein Mutants Containing a Single Cysteine in Either Nucleotide-binding Fold Abolishes Drug-stimulated ATPase Activity (*) , 1995, The Journal of Biological Chemistry.

[16]  P. Gros,et al.  Transmembrane Organization of Mouse P-glycoprotein Determined by Epitope Insertion and Immunofluorescence (*) , 1996, The Journal of Biological Chemistry.

[17]  F. Baas,et al.  The human mdr3 gene encodes a novel P‐glycoprotein homologue and gives rise to alternatively spliced mRNAs in liver. , 1987, The EMBO journal.

[18]  P. Gros,et al.  A single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdr1 and mdr3 drug efflux pumps. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Housman,et al.  Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins , 1986, Cell.

[20]  C. Slayman,et al.  Site-directed Mutagenesis of the Yeast PMA1 H+-ATPase STRUCTURAL AND FUNCTIONAL ROLE OF CYSTEINE RESIDUES (*) , 1995, The Journal of Biological Chemistry.

[21]  A. Schinkel,et al.  The physiological function of drug-transporting P-glycoproteins. , 1997, Seminars in cancer biology.

[22]  D. Clarke,et al.  Drug-stimulated ATPase Activity of Human P-glycoprotein Requires Movement between Transmembrane Segments 6 and 12* , 1997, The Journal of Biological Chemistry.

[23]  A. Pakula,et al.  Determination of transmembrane protein structure by disulfide cross-linking: the Escherichia coli Tar receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[24]  D. Clarke,et al.  Rapid Purification of Human P-glycoprotein Mutants Expressed Transiently in HEK 293 Cells by Nickel-Chelate Chromatography and Characterization of their Drug-stimulated ATPase Activities (*) , 1995, The Journal of Biological Chemistry.

[25]  D. Clarke,et al.  P-glycoprotein , 1995, The Journal of Biological Chemistry.

[26]  E. Zaki,et al.  Investigation of the Extracellular Accessibility of the Connecting Loop between Membrane Domains I and II of the Bradykinin B2 Receptor* , 1999, The Journal of Biological Chemistry.

[27]  D. Clarke,et al.  Superfolding of the Partially Unfolded Core-glycosylated Intermediate of Human P-glycoprotein into the Mature Enzyme Is Promoted by Substrate-induced Transmembrane Domain Interactions* , 1998, The Journal of Biological Chemistry.

[28]  A. Shapiro,et al.  Topological folding and proteolysis profile of P-glycoprotein in membranes of multidrug-resistant cells: implications for the drug-transport mechanism. , 1996, Biochemistry.

[29]  D. Housman,et al.  Isolation and expression of a complementary DNA that confers multidrug resistance , 1986, Nature.

[30]  S. Chervitz,et al.  Lock On/Off Disulfides Identify the Transmembrane Signaling Helix of the Aspartate Receptor (*) , 1995, The Journal of Biological Chemistry.

[31]  C. Higgins,et al.  The multidrug resistance and cystic fibrosis genes have complementary patterns of epithelial expression. , 1992, The EMBO journal.

[32]  Jing Chen,et al.  Determination of External Loop Topology in the Serotonin Transporter by Site-directed Chemical Labeling* , 1998, The Journal of Biological Chemistry.

[33]  I. Pastan,et al.  Characterization of the azidopine and vinblastine binding site of P-glycoprotein. , 1992, The Journal of biological chemistry.

[34]  D. Clarke,et al.  Membrane Topology of a Cysteine-less Mutant of Human P-glycoprotein (*) , 1995, The Journal of Biological Chemistry.

[35]  D. Clarke,et al.  Identification of Residues in the Drug-binding Site of Human P-glycoprotein Using a Thiol-reactive Substrate* , 1997, The Journal of Biological Chemistry.

[36]  T. Grogan,et al.  Diagnosis and reversal of multidrug resistance in paediatric cancers. , 1996, European journal of cancer.

[37]  E. Welker,et al.  Characterization of the human multidrug resistance protein containing mutations in the ATP-binding cassette signature region. , 1997, The Biochemical journal.

[38]  J. Casey,et al.  Topology of the Region Surrounding Glu681 of Human AE1 Protein, the Erythrocyte Anion Exchanger* , 1998, The Journal of Biological Chemistry.

[39]  L. Greenberger,et al.  Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12. , 1993, The Journal of biological chemistry.

[40]  D. Clarke,et al.  Correction of Defective Protein Kinesis of Human P-glycoprotein Mutants by Substrates and Modulators* , 1997, The Journal of Biological Chemistry.

[41]  V. Ling,et al.  Membrane topology of the N-terminal half of the hamster P-glycoprotein molecule. , 1993, The Journal of biological chemistry.

[42]  C. Higgins,et al.  The ABC of channel regulation , 1995, Cell.

[43]  I. Roninson,et al.  An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene , 1988, Cell.

[44]  D. Maclennan,et al.  Monoclonal antibodies to the Ca2+ + Mg2+-dependent ATPase of sarcoplasmic reticulum identify polymorphic forms of the enzyme and indicate the presence in the enzyme of a classical high-affinity Ca2+ binding site , 1984, Journal of bioenergetics and biomembranes.

[45]  M. Melamed,et al.  Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[46]  K Ueda,et al.  P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance. , 1989, Biochemical and biophysical research communications.

[47]  D. Housman,et al.  The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues , 1989, Molecular and cellular biology.

[48]  D. Clarke,et al.  Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein. , 1994, Biochemistry.

[49]  Eitan Bibi,et al.  Multidrug Resistance Protein (Mdr)-alkaline Phosphatase Hybrids in Escherichia coli Suggest a Major Revision in the Topology of the C-terminal Half of Mdr (*) , 1995, The Journal of Biological Chemistry.

[50]  V. Lingappa,et al.  Evidence for an alternate model of human P-glycoprotein structure and biogenesis. , 1993, The Journal of biological chemistry.

[51]  R. H. Fillingame,et al.  Transmembrane Topography of Subunit a in the Escherichia coli F1F0 ATP Synthase* , 1998, The Journal of Biological Chemistry.

[52]  K. Ueda,et al.  P-glycoprotein. ATP hydrolysis by the N-terminal nucleotide-binding domain. , 1992, The Journal of biological chemistry.

[53]  D. Clarke,et al.  The glycosylation and orientation in the membrane of the third cytoplasmic loop of human P-glycoprotein is affected by mutations and substrates. , 1999, Biochemistry.

[54]  R. Béliveau,et al.  Identification of the cyclosporin-binding site in P-glycoprotein. , 1998, Biochemistry.

[55]  L. Greenberger,et al.  Functional Evidence That Transmembrane 12 and the Loop between Transmembrane 11 and 12 Form Part of the Drug-binding Domain in P-glycoprotein Encoded by MDR1 (*) , 1995, The Journal of Biological Chemistry.

[56]  D. Koshland,et al.  Global flexibility in a sensory receptor: a site-directed cross-linking approach. , 1987, Science.

[57]  A. E. Senior,et al.  Covalent inhibitors of P-glycoprotein ATPase activity. , 1994, The Journal of biological chemistry.

[58]  I. Pastan,et al.  Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. , 1998, Biochemistry.

[59]  I. Pastan,et al.  Localization of the forskolin labeling sites to both halves of P-glycoprotein: similarity of the sites labeled by forskolin and prazosin. , 1994, Molecular pharmacology.

[60]  I. Pastan,et al.  Functional characterization of a glycine 185-to-valine substitution in human P-glycoprotein by using a vaccinia-based transient expression system. , 1996, Molecular biology of the cell.

[61]  P. Gros,et al.  Functional analysis of P-glycoprotein mutants identifies predicted transmembrane domain 11 as a putative drug binding site. , 1993, Biochemistry.

[62]  I. Pastan,et al.  HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. , 1998, Biochemistry.

[63]  D. Clarke,et al.  Inhibition of Oxidative Cross-linking between Engineered Cysteine Residues at Positions 332 in Predicted Transmembrane Segments (TM) 6 and 975 in Predicted TM12 of Human P-glycoprotein by Drug Substrates* , 1996, The Journal of Biological Chemistry.

[64]  M C Willingham,et al.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[65]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[66]  I. Pastan,et al.  P-glycoprotein and multidrug resistance. , 1996, Current opinion in genetics & development.

[67]  J. Endicott,et al.  Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance , 1986, Nature.

[68]  V. Ling,et al.  Study of membrane orientation and glycosylated extracellular loops of mouse P-glycoprotein by in vitro translation. , 1991, The Journal of biological chemistry.

[69]  Y. Tanigawara,et al.  Human P-glycoprotein transports cyclosporin A and FK506. , 1993, The Journal of biological chemistry.

[70]  D. Clarke,et al.  Reconstitution of drug-stimulated ATPase activity following co-expression of each half of human P-glycoprotein as separate polypeptides. , 1994, The Journal of biological chemistry.

[71]  A. E. Senior,et al.  The catalytic cycle of P‐glycoprotein , 1995, FEBS letters.

[72]  P. Gros,et al.  Functional Dissection of P-glycoprotein Nucleotide-binding Domains in Chimeric and Mutant Proteins , 1995, The Journal of Biological Chemistry.

[73]  S. Kuduk,et al.  Identification of the domains of photoincorporation of the 3'- and 7-benzophenone analogues of taxol in the carboxyl-terminal half of murine mdr1b P-glycoprotein. , 1998, Biochemistry.

[74]  Michael M. Gottesman,et al.  Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells , 1986, Cell.

[75]  M. Raida,et al.  Localization of the Iodomycin Binding Site in Hamster P-glycoprotein* , 1997, The Journal of Biological Chemistry.